Inherited retinal diseases such as Usher syndrome and Stargardt disease remain difficult to treat, particularly when the genes involved are too large for conventional gene therapy delivery systems. AAVantgarde is advancing its dual-AAV platform throu... Read more
Developing effective drug formulations remains a major challenge for biopharma companies, particularly for molecules with poor solubility or complex release requirements. Quotient Sciences is exploring how machine learning and integrated manufacturin... Read more
Bringing microbiome-based therapies to patients requires more than promising clinical results. Manufacturing complex mixtures of live bacteria consistently and at commercial scale remains a major challenge. MRM Health is addressing this through its p... Read more
For people living with hereditary angioedema (HAE), sudden and unpredictable swelling attacks can disrupt daily life and require urgent treatment. Pharvaris is developing deucrictibant, an investigational oral therapy designed to provide rapid reli... Read more
Bavarian Nordic A/S (OMX: BAVA) launches the second tranche of the share buy-back program announced on August 21, under which the Company intends to repurchase own shares for up to DKK 750 million. The second tranche will comprise buy-back of shares ... Read more
ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, announced the successful completion of the second close of its seed financing round, securing an additional €1.6 million, bringing... Read more
AR1001 met the primary endpoint in the prespecified Monotherapy population, with a CDR-SB treatment difference of -0.44 points versus placebo at Week 52 (p=0.0266), representing 31% slowing of clinical decline. The difference between treatment and p... Read more
DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer’s most important and historically undruggable drivers Cancer Research UK’s Centre for Drug Development has agreed to fund, sponso... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.